DS
OMED

DRW Securities’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

DRW Securities’s Portfolio OMED Stock Details OMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-53,740
Closed -$124K – 120
2018
Q2 		$124K Hold
53,740
– – 0.01% 86
2018
Q1 		$171K Buy
53,740
+40,000
+291% +$110K 0.01% 128
2017
Q4 		$56K Buy
+13,740
New +$59.8K 0.01% 447

Other funds holding OMED

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

DRW Securities's OMED Position: Q3 2018 in Review

DRW Securities sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q3 2018, closing a stake of 53,740 shares — an estimated $124K sold.

DRW Securities first reported a position in OMED in Q4 2017 and held it in 3 quarters. The position peaked at $171K in Q1 2018. 54 funds tracked by Wall St. Rank hold OMED as of Q3 2018.

  • DRW Securities reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
  • DRW Securities sold 53,740 OncoMed Pharmaceuticals, Inc. shares in Q3 2018, an estimated $124K.
  • DRW Securities first reported a position in OncoMed Pharmaceuticals, Inc. in Q4 2017 and held it in 3 quarters.
  • DRW Securities's OncoMed Pharmaceuticals, Inc. position peaked at $171K in Q1 2018.
  • 54 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q3 2018.

Based on DRW Securities's 13F filing for Q3 2018, filed 14 Nov 2018.